Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Cutaneous Neuroendocrine Carcinoma

Cutaneous Neuroendocrine Carcinoma — NIH Grants & Funding

Active and recent NIH-funded research on Cutaneous Neuroendocrine Carcinoma. Data from NIH RePORTER, last 36 months.

MONDO:0019210

NIH-funded research on Cutaneous Neuroendocrine Carcinoma

active grants

institutions

researchers

new in last 12 mo.

$37.8M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(14)

Basic ScienceP01Active

Immunobiology and Immune Therapy for Merkel Cell Carcinoma

NGHIEM, PAUL·UNIVERSITY OF WASHINGTON·SEATTLE, WA

$2,994,993 (FY2025)

Cutaneous Neuroendocrine Carcinoma — NIH Grants & Funding

Basic Science(14)

Immunobiology and Immune Therapy for Merkel Cell Carcinoma

Biology of Virus-associated Cancers

Molecular pathogenesis and therapy innovation for Merkel cell carcinoma

Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations

Mechanism For Merkel Cell Polyomavirus Persistence

Role of Merkel cell polyomavirus small T antigen in persistent infection

Utilization of a novel dissimilarity approach to identify a novel mechanism of Merkel cell polyomavirus small tumor antigen nuclear import responsible for the development of Merkel cell carcinoma

Unraveling the regulatory circuits that drive Merkel cell carcinoma

Understanding B cell immunity in Merkel cell carcinoma

Deciphering the mechanisms of nucleolar stress response during MCPyV infection

Translational(5)

Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy

Repurposing drugs and finding new therapeutic targets for cutaneous malignancies

Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment

Targeting MCPyV oncogene transcription to suppress tumorigenesis

Phase I Therapeutic Award: A Novel Engineered Bacterial Anticancer Immunotherapy for Merkel Cell Carcinoma

Clinical(3)

Clinical treatment of advanced Merkel cell carcinoma

Merkel cell polyomavirus infection, host response, and viral oncogenic mechanism

Hijacking host cellular motors for the nuclear entry of polyomaviruses